Camzyos treat obstructive hypertrophic cardiomyopathy
Drug Approval Name: Camzyos Active Ingredient: mavacamten Indications: To treat certain classes of obstructive hypertrophic cardiomyopathy Approval Date: 4/28/2022 Company: MyoKardia, Inc., a wholly-owned subsidiary of Bristol Myers Squibb More: …